Prognostic Effects of Imaging Ratios in Idiopathic Pulmonary Fibrosis
Investigators sought to determine a potential link between mPA/Ao ratio at diagnosis and clinical characteristics and outcomes in patients with idiopathic pulmonary fibrosis.
Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis Outcomes Similar With Pneumonia or Acute Exacerbation
Based on the 2016 International Working Group (IWG) diagnostic criteria for idiopathic pulmonary fibrosis (IPF), outcomes are relatively similar between patients with IPF with pneumonia and patients with an acute IPF exacerbation.
Recombinant Human Pentraxin-2 Gets Breakthrough Tx Designation for Idiopathic Pulmonary Fibrosis
A novel treatment for idiopathic pulmonary fibrosis, PRM-151, has been granted Breakthrough Therapy designation by the FDA.
Idiopathic Pulmonary Fibrosis Prognosis Predicted by CT Parameters
Patients with idiopathic pulmonary fibrosis with better CT indices such as FEV1 and mean lung attenuation had improved outcomes.
Lung CT Helps Predict Severity, Mortality in Idiopathic Pulmonary Fibrosis
Researchers retrospectively analyzed the association among physiologic measurements, survival, and quantitative high-resolution computed tomographic indices in patients with idiopathic pulmonary fibrosis.
Pirfenidone Slows Long-Term Progression of Idiopathic Pulmonary Fibrosis
Fewer than 25% of patients with idiopathic pulmonary fibrosis who were treated with the antifibrotic drug pirfenidone showed signs of disease progression.
Summary of 2018 Idiopathic Pulmonary Fibrosis Diagnostic Guidelines
A new clinical practice guidelines summary for clinicians regarding idiopathic pulmonary fibrosis has been released, which describes clinical manifestations and diagnostic interventions for the disease.
New Idiopathic Pulmonary Fibrosis Treatment Safe, Likely Effective
Oral PBI-4050 alone or in combination with nintedanib or pirfenidone was well tolerated and associated with no serious adverse events in patients with idiopathic pulmonary fibrosis.
Prophylactic Azithromycin Beneficial in Idiopathic Pulmonary Fibrosis
Prophylactic azithromycin may reduce hospital stays and the need for rescue antibiotics in patients with idiopathic pulmonary fibrosis.
Hypersensitivity Pneumonitis Prognosis by Phenotype
Compared with idiopathic pulmonary fibrosis, nonhoneycomb hypersensitivity pneumonitis phenotypes are associated with greater improvements in percent-predicted forced vital capacity.
Next post in Restrictive Lung Disease
